Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Search Results

Refine Your Search

By Sector
Sort by: Date|Relevance

Protalix Shares Trade up 70% Upon Release of Phase 3 Fabry Disease Data

Shares of Protalix Biotherapeutics skyrocketed today on much higher than average volume as the firm announced positive 12-month interim data from its BRIDGE Phase 3 open label switch-over study of pegunigalsidase alfa (PRX-102) for the treatment of Fabry disease. Earl...
Streetwise Reports | October 18, 2019 |

Ultragenyx Shares Increase 30% on Results from Phase 1/2 OTC Deficiency Study

Rare disease biopharmaceutical company Ultragenyx Pharmaceutical's shares traded 30% higher after the firm reported positive topline results from Cohorts 2 and 3 in its Phase 1/2 study of DTX301 gene therapy in Ornithine Transcarbamylase Deficiency. After U.S. markets...
Streetwise Reports | January 13, 2020 |

Biotech's New Mesothelioma Trial Data Show Efficacy, Immunogenicity

These results of a study evaluating Targovax's lead candidate are reviewed and commented on in an H.C. Wainwright & Co. report. In a June 22 research note, H.C. Wainwright & Co. analyst Joseph Pantginis reported that Targovax ASA's (TRVX:OSE) ONCOS-102, in trial ...
Streetwise Reports | June 25, 2020 |

Foot Locker Shares Trip and Fall on Lower Than Expected Earnings

Foot Locker Inc. shares set a 52-week intraday low after the firm reported Q2/19 earnings. The firm's shares are trading down more than 18% compounded by a day of market worries from China tariffs escalation. Global specialty athletic retailer Foot Locker Inc. (FL:NY...
Streetwise Reports | August 26, 2019 |

Syros Pharma Teams Up with Global Blood Therapeutics to Fight Sickle Cell Disease

Syros Pharmaceuticals' shares rose 20% today after the firm reported that it entered into a collaboration agreement with Global Blood Therapeutics for development of therapies for sickle cell disease and beta thalassemia that could result in payments to Syros as high as $315 m...
Streetwise Reports | December 19, 2019 |

Coverage Initiated on Immunotherapies Developer with 'Catalyst Rich 2020'

The key business and investment points are presented in a ROTH Capital Partners report. In a Dec. 18 research note, analyst Jonathan Aschoff reported that ROTH Capital Partners initiated coverage on Inovio Pharmaceuticals Inc. (INO:NASDAQ) with a Buy rating and a "c...
Streetwise Reports | December 27, 2019 |

iBio Shares Trade Up 40% After Announcing Development of Proprietary COVID-19 Vaccine Candidates

iBio Inc. shares traded higher after the company reported that it has filed several provisional patents for its SARS-CoV-2 Virus-Like Particle platform with the U.S. Patent and Trademark Office. Biologics contract manufacturing firm iBio Inc. (IBIO:NYSE.Ame...
Streetwise Reports | March 19, 2020 |

Almonty fires up the turbo: Reaching new heights with tungsten and foresight

(Source: Pixabay ) Stockhouse does not provide investment advice or recommendations. All investment decisions should be made based on your own research and consultation with a registered investment professional. The issuer is solely responsible for the accuracy of th...
André Will-Laudien | July 4, 2025 |

THE BIG D

According to Investopedia (even though the National Bureau of Economics has redefined it), “a recession is a macroeconomic term that refers to a significant decline in general economic activity in a designated region. It had been typically recognized as two consecutive quart...
Dr. Kal Kotecha | May 20, 2020 |

New EU initiative boosts the hydrogen market! Pure Hydrogen, Nel, and SFC Energy stand to benefit!

With the Hydrogen Mechanism, the EU has launched a new and important instrument on the market. The launch took place just two weeks ago, so it is still too early to draw any interim conclusions. However, the approach has the potential to take the hydrogen market to a new ...
Carsten Mainitz | November 26, 2025 |
1 2 3 4 5 6 7 8 9 10 ...